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Abstract
Background: Angiogenesis, the sprouting of capillaries from existing blood vessels, is central to
tumour growth and progression, however the molecular regulation of this process remains to be
fully elucidated. The secreted glycoprotein osteoprotegerin (OPG) is one potential pro-angiogenic
factor, and clinical studies have demonstrated endothelial cells within a number of tumour types to
express high levels of OPG compared to those in normal tissue. Additionally, OPG can increase
endothelial cell survival, proliferation and migration, as well as induce endothelial cell tube
formation in vitro. This study aims to elucidate the processes involved in the pro-angiogenic effects
of OPG in vitro, and also how OPG levels may be regulated within the tumour microenvironment.
Results: It has previously been demonstrated that OPG can induce tube formation on growth
factor reduced matrigel. In this study, we demonstrate that OPG enhances the pro-angiogenic
effects of VEGF and that OPG does not stimulate endothelial cell tube formation through activation
of the VEGFR2 receptor. We also show that cell contact between HuDMECs and the T47D breast
cancer cell line increases endothelial cell OPG mRNA and protein secretion levels in in vitro co-
cultures. These increases in endothelial cell OPG secretion were dependent on ανβ3 ligation and
NFκB activation. In contrast, the pro-angiogenic factors VEGF, bFGF and TGFβ had no effect on
HuDMEC OPG levels.
Conclusion: These findings suggest that the VEGF signalling pathway is not involved in mediating
the pro-angiogenic effects of OPG on endothelial cells in vitro. Additionally, we show that breast
cancer cells cause increased levels of OPG expression by endothelial cells, and that direct contact
between endothelial cells and tumour cells is required in order to increase endothelial OPG
expression and secretion. Stimulation of OPG secretion was shown to involve ανβ3 ligation and
NFκB activation.
Background
Angiogenesis, the sprouting of capillaries from existing
blood vessels, is central to tumour growth and progres-
sion and the balance between pro-angiogenic and anti-
angiogenic factors is thought to regulate this process [1].
Factors such as vascular endothelial growth factor (VEGF),
fibroblast growth factor (FGF) and the angiopoietins are
well-established promoters of angiogenesis. However, the
molecular regulation of tumour angiogenesis remains to
be fully elucidated [2].
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One potential pro-angiogenic factor is osteoprotegerin
(OPG) [3,4]. OPG is a secreted glycoprotein belonging to
the tumour necrosis factor receptor (TNFR) superfamily,
initially identified for its role in regulating bone turnover
through the binding and neutralisation of receptor activa-
tor of NFκB ligand (RANKL). Subsequently OPG has been
found to have additional roles within the immune and
vascular systems, as well as promoting tumourigenesis
[5]. Observations that OPG deficient mice exhibit vascular
calcification provided initial evidence that OPG could
have a role in the vascular system and further in vivo stud-
ies have demonstrated the involvement of OPG in vascu-
lar complications, including atherosclerotic plaque
calcification [6-8]. These findings have been supported
clinically, with both OPG polymorphisms and increased
serum levels being associated with an increased risk of
coronary artery disease [9-11]. Additionally, OPG has
been associated with other vascular complications,
including ischaemic stroke and pulmonary arterial hyper-
tension [12,13]. With reference to in vitro studies OPG has
been found to increase endothelial cell survival, prolifera-
tion and migration, as well as induce endothelial cell tube
formation in an in vitro matrigel model of angiogenesis
[3,14]. Recently, αν integrin has been found to be involved
in OPG-induced endothelial cell migration and prolifera-
tion, however mechanisms for other potential pro-ang-
iogenic effects such as OPG-stimulated tube formation
remain to be established [14].
Clinical studies have shown endothelial cells within a
number of tumour types to express high levels of OPG
compared with those in normal tissues, and in breast can-
cer this expression was found to correlate with tumour
grade [3]. In vitro, endothelial cells have been found to
secrete OPG capable of inhibiting tumour necrosis factor
(TNF)-related apoptosis inducing ligand (TRAIL)-induced
apoptosis of breast cancer cells, indicating endothelial-
derived OPG to be functionally active [3]. Other studies
have demonstrated the ability of OPG to inhibit TRAIL-
induced apoptosis of a variety of cancer cell lines [15-17].
Therefore, it is possible that OPG can promote tumouri-
genesis both directly, via pro-survival actions on tumour
cells and also indirectly, through the stimulation of angio-
genesis. Previous studies have found endothelial cell OPG
levels to be up-regulated in response to pro-inflammatory
factors including IL-1α and TNFα [18]. However, proc-
esses involved in regulating endothelial OPG levels in the
tumour microenvironment are currently unknown.
Therefore, this study aims to address two key points.
Firstly, to elucidate the mechanisms behind the pro-ang-
iogenic effects of OPG and secondly, to establish whether
this is relevant in the tumour microenvironment.
Results
Effect of VEGF in combination with OPG on endothelial 
cell tube formation
It has previously been shown that OPG can induce
endothelial cell tube formation on growth factor reduced
matrigel [3]. However, in the tumour microenvironment
it is possible that OPG also enhances vessel formation
induced by other pro-angiogenic factors such as VEGF.
Therefore, to further elucidate how OPG may affect tube
formation, endothelial cells were treated with a combina-
tion of OPG and VEGF to establish whether the two have
a synergistic effect on tube formation in vitro. As demon-
strated in figure 1, OPG or VEGF when administered
alone significantly increased tube formation, almost dou-
bling the number of branch points (p < 0.001). When
OPG and VEGF were added together, tube formation was
significantly increased by 20% compared to VEGF alone
(p < 0.001) and 26% compared to OPG alone (p < 0.001).
This suggests that within the tumour microenvironment
OPG is able to act in concert with other pro-angiogenic
factors such as VEGF to further enhance angiogenesis and
additionally, that OPG and VEGF act via different path-
ways to induce endothelial cell tube formation.
To confirm this, the levels of HuDMEC tube formation
induced by either OPG or VEGF were determined in the
presence or absence of a VEGFR2 neutralising antibody.
As demonstrated in figure 2, both VEGF and OPG stimu-
lated HuDMEC tube formation on growth factor reduced
matrigel compared to control. VEGF-induced tube forma-
tion was inhibited in the presence of the anti-VEGFR2
antibody as observed by a 60% decrease in branchpoint
number (p < 0.001). In contrast, administration of the
anti-VEGFR2 antibody had no effect on OPG-induced
tube formation, suggesting that OPG does not induce
tubule formation through interacting with the VEGFR2
receptor (Figure 2).
Effect of pro-angiogenic factors on endothelial cell OPG 
production
One potential mechanism by which endothelial cell OPG
production may be elevated within the tumour microen-
vironment is through endothelial cell stimulation by pro-
angiogenic factors. To assess the ability of pro-angiogenic
factors to affect the levels of endothelial OPG production,
HuDMECs were treated for 24 hours with VEGF (1–25 ng/
ml), TGFβ (5–10 ng/ml) or FGF (10–25 ng/ml), as well as
the pro-inflammatory cytokine TNFα (1–50 ng/ml),
which has previously been shown to stimulate endothe-
lial OPG production [18,19]. Levels of gene expression
were then determined using real-time PCR and OPG
secretion assessed using ELISA. As demonstrated in figure
3(a), TNFα significantly increased HuDMEC OPG gene
expression and at 10 ng/ml, expression levels were 6-fold
greater than untreated HuDMECs (p < 0.05). Similarly,Molecular Cancer 2009, 8:49 http://www.molecular-cancer.com/content/8/1/49
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OPG secretion levels were significantly increased (p  <
0.001 at 10 ng/ml and 50 ng/ml) (Figure 3(b)), confirm-
ing previous studies in endothelial cells [18-20]. In con-
trast, no significant change in OPG expression or secretion
was detected after HuDMEC were treated with VEGF,
TGFβ or FGF (Figure 3(c), (d), (e), (f), (g) and 3(h)). This
suggests that some of the key pro-angiogenic factors do
not have a central role in enhancing endothelial cell OPG
levels.
Effects of tumour cells on endothelial cell OPG production
An alternative mechanism by which OPG production by
HuDMECs might be enhanced is through direct contact
with tumour cells. Since clinical studies have demon-
strated increased OPG expression in breast tumour
endothelial cells, HuDMECs were co-cultured with the
T47D breast cancer cell line, which did not produce
detectable levels of OPG (data not shown). These co-cul-
tures were established at HuDMEC: T47D ratios of 2:1,
4:1 and 10:1. Following a 72-hour incubation period,
HuDMECs were separated from the T47D cells using
Effect of VEGF in combination with OPG on endothelial cell tube formation Figure 1
Effect of VEGF in combination with OPG on endothelial cell tube formation. HuDMECs were cultured on growth 
factor reduced matrigel for 8 hours and branch point number counted as described in materials and methods. (a) Untreated 
control, (b) OPG 10 ng/ml, (c) VEGF 1 ng/ml, (d) OPG 10 ng/ml and VEGF 1 ng/ml. (e) Quantification of tube formation 
through measurement of branch point number. Data represented as mean ± S.E.M. from three independent experiments per-
formed in triplicate. ***, p < 0.001 compared to VEGF (1 ng/ml), OPG (10 ng/ml) or untreated control; +++, p < 0.001 com-
pared to untreated control only.Molecular Cancer 2009, 8:49 http://www.molecular-cancer.com/content/8/1/49
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CD31 Dynabeads and OPG gene expression assessed in
each cell type. As demonstrated in figure 4(a), tumour cell
contact significantly increased OPG gene expression levels
compared to HuDMECs cultured alone. This was particu-
larly noticeable at a 2:1 HuDMEC: T47D ratio, where
OPG levels were increased 3-fold (p < 0.001). This was
specific to HuDMECs as OPG gene expression was not
detectable in the T47D cells following co-culture. The ele-
vated levels of OPG expression were accompanied by
increased HuDMEC OPG secretion. This increase was sig-
nificant in co-cultures with a 2:1 HuDMEC: T47D ratio
(100 pg/1000 cells) compared to HuDMECs cultured
alone (42 pg/1000 cells) (p < 0.01) (Figure 4(b)). The
increase in OPG expression seen in the co-cultures was
dependent on direct cell-cell contact, as addition of condi-
tioned medium from T47D monolayers had no effect on
HuDMEC OPG levels (data not shown).
Tumour cell contact-mediated HuDMEC OPG production 
involves NFkB and integrin ανβ3
Previous studies have demonstrated both the bacterial
pathogen Porphyromonas gingivalis and the secreted glyco-
protein osteopontin to increase endothelial cell OPG pro-
duction in an NFκB-dependent manner [4,21]. To
determine the involvement of NFkB in tumour cell con-
tact-mediated HuDMEC production, co-cultures were
established as previously and treated with the NFkB inhib-
itor PDTC (50 μM). As shown in figure 5(a), the tumour
cell contact-mediated increase in HuDMEC OPG secre-
tion was attenuated following NFκB inhibition with
Involvement of the VEGF receptor VEGFR2 in OPG mediated endothelial tube formation Figure 2
Involvement of the VEGF receptor VEGFR2 in OPG mediated endothelial tube formation. HuDMECs were cul-
tured on growth factor reduced matrigel for 8 hours and branch point number counted as described in materials and methods. 
(a) Untreated control, (b) VEGF 10 ng/ml, (c) VEGF 10 ng/ml and VEGFR2 neutralising antibody (1 μg/ml), (d) OPG 100 ng/ml, 
(e) OPG 100 ng/ml and VEGFR2 neutralising antibody (1 μg/ml). (f) Quantification of tube formation through measurement of 
branch point number. Data represented as mean ± S.E.M. from three independent experiments performed in triplicate. ***, p < 
0.001 compared to VEGF in combination with VEGFR2 antibody; NS, no significant difference.Molecular Cancer 2009, 8:49 http://www.molecular-cancer.com/content/8/1/49
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Effect of pro-angiogenic factors on endothelial cell OPG production Figure 3
Effect of pro-angiogenic factors on endothelial cell OPG production. HuDMECs were treated with increasing con-
centrations of TNFα (a) and (b), VEGF (c) and (d), TGFβ (e) and (f), or FGF (g) and (h) for 24 hours. Conditioned medium was 
collected and OPG secretion measured using ELISA as described in materials and methods. RNA was extracted and gene 
expression quantified using real-time PCR. For real-time quantitative PCR, values were normalised to GAPDH and are given as 
fold expression compared to untreated HuDMECs. Data are represented as mean ± S.E.M. from three independent experi-
ments performed in triplicate. ***, p < 0.001 compared to untreated control; **, p < 0.01 compared to untreated control; *, p 
< 0.05 compared to control.Molecular Cancer 2009, 8:49 http://www.molecular-cancer.com/content/8/1/49
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PDTC. Whilst untreated co-cultures at a 2:1 HuDMEC:
T47D ratio secreted 30 pg/1000 cells of OPG, this was
decreased by 53% to 14 pg/1000 cells in those treated
with the PDTC (p < 0.001). In contrast, NFkB inhibition
did not affect the tumour cell contact-mediated increase
in HuDMEC OPG gene expression, suggesting NFκB
involvement at the post-transcriptional level (Figure
5(b)). As a control, the effect of NFκB inhibition on TNFα
induced HuDMEC OPG production was assessed. As
demonstrated in figure 6, in contrast to the co-cultures,
the TNFα mediated increase in both HuDMEC OPG gene
expression and secretion was attenuated following treat-
ment with PDTC. In terms of gene expression, PDTC sig-
nificantly inhibited the TNFα mediated increase in OPG
levels (p < 0.001). Similarly, whilst treatment of HuD-
MECs with TNFα significantly increased OPG secretion
from 74.53 pg/1000 cells to 1065 pg/1000 cells (p  <
0.001), in the presence of PDTC this was significantly
decreased to 5.76 pg/1000 cells (p < 0.001).
In endothelial cells, NFkB-dependent OPG production
has previously been found to involve integrin ανβ3 liga-
tion [4]. We therefore investigated whether this mecha-
nism could be involved in tumour cell contact-mediated
HuDMEC OPG production. To address this issue, co-cul-
tures were established as previously and treated with an
integrin  ανβ3 neutralising antibody (10 μg/ml) for 72
hours. As demonstrated in figure 7(a), the tumour cell
contact-mediated increase in OPG secretion by HuDMEC
was inhibited following integrin ανβ3  neutralisation.
Whilst untreated co-cultures at a 2:1 HuDMEC:T47D ratio
secreted 20 pg/1000 cells of OPG, this was decreased by
over 50% to 9 pg/1000 cells in those treated with the
integrin  ανβ3 neutralising antibody (p  < 0.05). As was
observed for NFκB inhibition, integrin ανβ3 neutralisation
did not affect the tumour cell contact-mediated increase
in HuDMEC OPG gene expression, suggesting involve-
ment at the post-transcriptional level (Figure 7(b)).
Discussion
This study has looked at two key aspects of OPG in
endothelial cell biology, with a particular focus on the
potential role of OPG in tumour angiogenesis. Firstly, the
involvement of the VEGFR2 signalling pathway in OPG-
mediated endothelial cell tube formation has been elimi-
nated, narrowing the search for the mechanism involved
in this process. Secondly, we have demonstrated the
requirement for tumour cell contact in increasing OPG
production in endothelial cells, a process partly depend-
ent on integrin ανβ3 ligation and activation of the NFκB
pathway. These findings could give an important insight
Effect of tumour cell contact on endothelial cell OPG pro- duction Figure 4
Effect of tumour cell contact on endothelial cell OPG 
production. HuDMECs were co-cultured with the T47D 
cell line at HuDMEC: T47D ratios of 2:1, 4:1 and 10:1 for 72 
hours as described in materials and methods. HuDMECs 
were separated from the T47D cell line and gene expression 
measured in the separate cell populations using real-time 
quantitative PCR (a). OPG secretion was assessed using 
ELISA (b). For real-time quantitative PCR, values were nor-
malised to GAPDH and are given as fold expression com-
pared to untreated HuDMECs. Data are represented as 
mean ± S.E.M. from three independent experiments. ***, p < 
0.001 compared to control cells (HuDMEC only); **, p < 0.01 
compared to control.
Effect of NFκB inhibition on tumour cell contact mediated  endothelial cell OPG production Figure 5
Effect of NFκB inhibition on tumour cell contact 
mediated endothelial cell OPG production. HuDMECs 
were co-cultured with the T47D cell line at HuDMEC: T47D 
ratios of 2:1, 4:1 and 10:1 for 72 hours in the presence or 
absence of the NFκB inhibitor PDTC as described in materi-
als and methods. HuDMECs were separated from the T47D 
cell line and gene expression measured in the separate popu-
lations. OPG secretion was assessed using ELISA (a) and gene 
expression measured using real-time quantitative PCR (b). 
For real-time quantitative PCR, values were normalised to 
GAPDH and are given as fold expression compared to 
untreated HuDMECs. Data are represented as mean ± S.E.M. 
from three independent experiments. ***, p < 0.001 com-
pared to HuDMEC: T47D 2:1 ratio co-culture without 
PDTC.Molecular Cancer 2009, 8:49 http://www.molecular-cancer.com/content/8/1/49
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into the processes involved in the proposed increased
OPG levels within the tumour microenvironment.
OPG has previously been found to induce endothelial cell
tube formation in an in vitro matrigel model of angiogen-
esis [3]. However, the mechanisms responsible for this are
unknown. In this study, OPG in combination with VEGF
was found to have an additive effect on endothelial cell
tube formation compared to either of the two treatments
alone. This additive effect does not appear to be exclusive
to OPG, since other studies have demonstrated similar
observations in endothelial cells treated with a combina-
tion of VEGF and bFGF [22,23]. Therefore, these results
suggest that within the tumour microenvironment, where
a variety of pro-angiogenic factors are likely to be present,
these can act in concert to promote tumour angiogenesis.
Additionally, our results show that OPG is unlikely to
induce endothelial cell tube formation via the same
mechanism as VEGF. Investigating this further, we found
that neutralisation of the VEGF receptor VEGFR2 had no
effect on OPG-mediated endothelial cell tube formation,
whilst significantly inhibiting that of VEGF. Although
VEGF is able to exert its effects through a number of recep-
tors, our results combined suggest it is probable that OPG
acts via an alternative mechanism.
One possible mechanism could be via the interaction of
OPG with heparan sulphate proteoglycans of the synde-
can family, which have previously been reported to be
involved in OPG-mediated monocyte chemotaxis [24].
Additionally, the observation that the syndecan binding
peptide AG73 can induce endothelial cell tube formation
suggests the involvement of syndecans in this process
[25]. In our study recombinant Fc-conjugated OPG was
used, the heparin binding ability of which is suggested to
be compromised [26]. However, other studies have
shown both OPG and OPG-Fc to bind to cells in an appar-
ently heparan sulphate-dependent manner [27,28].
Therefore the potential involvement of the syndecans in
OPG-mediated endothelial cell tube formation cannot be
completely dismissed. OPG has previously been observed
to bind to the anti-angiogenic protein thrombospondin-1
(TSP-1) [29]. TSP-1 is released by endothelial cells and
inhibition of TSP-1 activity using blocking antibodies pro-
motes endothelial cell tube formation [30]. Therefore,
another consideration could be that OPG binds to and
inhibits TSP-1 activity, resulting in an increase in endothe-
lial cell tube formation. Additionally, it would be of inter-
est to assess the role of the integrins in this process, given
recent evidence of their role in OPG-mediated endothelial
cell migration [14].
We have also demonstrated that tumour cell contact, but
not the pro-angiogenic factors VEGF, bFGF or TGFβ,
enhance OPG production in microvascular endothelial
Effect of NFκB inhibition on TNFα mediated endothelial cell  OPG production Figure 6
Effect of NFκB inhibition on TNFα mediated 
endothelial cell OPG production. HuDMECs were 
treated with the NFκB inhibitor PDTC (50 μM), TNFα (10 
ng/ml) or TNFα (10 ng/ml) in conjunction with PDTC (50 
μM) for 24 hours. RNA was extracted and gene expression 
quantified using real-time PCR (a). For real-time quantitative 
PCR, values were normalised to GAPDH and are given as 
fold expression compared to untreated HuDMECs. OPG 
secretion was measured in the conditioned medium using 
ELISA as described in materials and methods (b). Data are 
represented as mean ± S.E.M. from three independent exper-
iments performed in triplicate. ***, p < 0.001.
Effect of integrin ανβ3 neutralisation on tumour cell contact  mediated endothelial cell OPG production Figure 7
Effect of integrin ανβ3 neutralisation on tumour cell 
contact mediated endothelial cell OPG production. 
HuDMECs were co-cultured with the T47D cell line at HuD-
MEC: T47D ratios of 2:1, 4:1 and 10:1 for 72 hours, in the 
presence or absence of an integerin ανβ3 neutralising anti-
body as described in materials and methods. HuDMECs were 
separated from the T47D cell line and gene expression meas-
ured in the separate cell populations. OPG secretion was 
assessed using ELISA (a) and gene expression measured using 
real-time quantitative PCR (b). For real-time quantitative 
PCR, values were normalised to GAPDH and are given as 
fold expression compared to untreated HuDMECs. Data 
represented as mean ± S.E.M. from three independent 
experiments. *, p < 0.05 compared to HuDMEC: T47D 2:1 
ratio co-culture without the integrin ανβ3 neutralising anti-
body.Molecular Cancer 2009, 8:49 http://www.molecular-cancer.com/content/8/1/49
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cells. In agreement with previously published studies, we
found that the proinflammatory cytokine TNFα increased
HuDMEC OPG levels, supporting that the cells used in
this study retained the responsiveness to cytokines [18-
20]. The role of TGFβ in regulating OPG levels has been
studied in other cell types, but the effects appear to
depend on the cell type used. Whilst TGFβ can increase
OPG production in osteoblasts and bone marrow stromal
cells, levels have been found to be decreased in human
vascular smooth muscle cells [31-33]. This suggests along
with our findings, that with regards to vascular cells, the
role of TGFβ in increasing OPG levels is negligible, at least
in vitro.
Although VEGF has previously been found to increase
OPG production in endothelial cells in combination with
TNFα [34], no study until now has assessed the effects of
VEGF alone. Our findings demonstrate that VEGF admin-
istered alone has no effect on endothelial cell OPG pro-
duction. Tumours often exhibit an inflammatory
component and it may be possible under those condi-
tions that VEGF could act in conjunction with TNFα to
augment OPG levels. However, in studies demonstrating
increased endothelial cell OPG expression in breast cancer
tissues, no notable inflammation was observed, suggest-
ing alternative mechanisms exist [3].
Another way in which endothelial cell OPG expression
may be enhanced within the tumour microenvironment
is through direct tumour cell contact. This is the first study
to demonstrate that contact between breast cancer cells
and endothelial cells results in increased gene and protein
levels of endothelial OPG, a process that appears to
depend on integrin ανβ3 ligation and activation of the
transcription factor NFκB. Interestingly, inhibition of
NFκB and integrin ανβ3 did not induce tumour cell con-
tact mediated increases in OPG gene expression in HuD-
MEC, indicating their involvement at the post
transcriptional level, possibly by affecting mechanisms
involved in mediating OPG secretion. Observations that
tumour cell conditioned medium had no effect on
endothelial cell OPG levels suggests this process requires
direct tumour cell contact. However, it cannot be ruled
out that contact between tumour and endothelial cells
results in the secretion of as yet unidentified factors from
tumour cells that are capable of inducing endothelial cell
OPG production. One potential candidate is the secreted
glycoprotein and integrin ανβ3 ligand osteopontin, which
has previously been observed to increase endothelial OPG
levels in an NFκB dependent manner following integrin
ανβ3 binding [4]. Interestingly, osteopontin expression
has been found to be increased in prostate cancer cells fol-
lowing their direct cell contact with bone marrow stromal
cells [35]. Therefore it is feasible to consider that oste-
opontin could be increased in other tumour-derived cell
lines following direct cell contact.
Conclusion
To conclude, this study has demonstrated that the VEGF
signalling pathway is not involved in mediating the pro-
angiogenic effects of OPG on endothelial cells in vitro,
thus narrowing the search for the mechanism by which
these processes occur. Secondly, this is the first study to
show that endothelial cell OPG is increased following
direct contact with breast tumour cells via a mechanism
that depends partly on integrin ανβ3 ligation and NFκB
activation. Therefore, observed increases of endothelial
OPG in malignant tissue, particularly that of breast can-
cer, could be a result of direct interactions between
tumour and endothelial cells within the tumour microen-
vironment. Our data support a potential role for endothe-
lial cell-derived OPG in tumour angiogenesis.
Methods
Cell culture
Human dermal microvascular endothelial cells (HuD-
MECs) were extracted from excess tissue, with the patients'
informed consent, following routine breast surgery
(kindly provided by Professor M. W. Reed, Royal Hallam-
shire Hospital, Sheffield, UK; Ethics number: SSREC98/
198). Cells were grown in T75 tissue culture flasks in basic
medium (EBM2) containing growth supplements (EGM-
2MV, Lonza, Wokingham, UK). All cells used in this study
were between passages 3 and 7. The T47D human breast
cancer cell line (American Type Culture Collection, Man-
assas, Virginia, USA) was maintained in RPMI 1640 (Inv-
itrogen, Paisley, UK) supplemented with foetal calf serum
(10%) and L-glutamine (2 mM).
Tubule formation assay
Recombinant human VEGF 165 and recombinant human
OPG/Fc chimera were purchased from R & D Systems
(Abingdon, UK). HuDMECs were trypsinised, washed
with PBS, counted and resuspended in EBM2 containing
1% FBS with VEGF (1 ng/ml), OPG (10 ng/ml) or VEGF
(1 ng/ml) in combination with OPG (10 ng/ml). For
experiments investigating the effect of VEGFR2 neutralisa-
tion HuDMECs were resuspended in EBM2 containing
VEGF (10 ng/ml), OPG (100 ng/ml), VEGF (10 ng/ml) in
combination with 1 μg/ml VEGFR2 neutralising antibody
(R & D systems (Abingdon, UK) or OPG (100 ng/ml) in
combination with 1 μg/ml VEGFR2 neutralising antibody.
Cells were seeded at a density of 2 × 104 cells/well onto
solidified growth factor reduced Matrigel (BD Biosciences,
Oxford, UK) in 24 well plates and incubated at 37°C for
8 hours. Tubular/cord-like networks were visualised with
an inverted light microscope (4× objective), photo-
graphed and tube formation assessed by counting branch
point number, using 3 fields per well.Molecular Cancer 2009, 8:49 http://www.molecular-cancer.com/content/8/1/49
Page 9 of 10
(page number not for citation purposes)
Treatment of HuDMECs with pro-angiogenic factors
Recombinant human TNFα, recombinant human VEGF
165, bFGF and recombinant human TGFβ were all pur-
chased from R & D systems (Abingdon, UK). HuDMECs
were seeded onto 24 well plates at a density of 1 × 104
cells/well in EGM-2MV containing TNFα (1, 10 and 50
ng/ml), VEGF (1,10 and 25 ng/ml), bFGF (10–25 ng/ml)
or TGFβ (5 and 10 ng/ml). After 24 hours incubation,
conditioned medium was removed for ELISA and RNA
extracted from treated cells for real-time quantitative PCR.
Co-culture of HuDMECs and T47D cells
HuDMECs and T47D cells were seeded into T25 tissue
culture flasks at HuDMEC: T47D ratios of 2:1, 4:1 and
10:1 and cultured in basic medium (EBM2) containing
growth supplements (EGM-2MV). After 72 hours incuba-
tion, conditioned medium was removed for ELISA and
the co-cultures trypsinised and centrifuged at 1,000 rpm
for 5 minutes. The pellet was resuspended in EGM-2MV
containing washed CD31 coated Dynabeads (25 μl per ml
of cell suspension) (Invitrogen, Paisley, UK) and incu-
bated at 4°C with end over end rotation. After 20 minutes,
the solution was placed in a Dynal MPC™ magnet for 3
minutes, allowing the endothelial cells and beads to form
a pellet. The supernatant containing T47D cells was trans-
ferred to a separate tube. This step was repeated a further
2 times, after which the RNA was extracted from both cell
types for real-time quantitative PCR.
For studies assessing the effect of NFκB inhibition, cells
were cultured as stated above in the presence or absence
of the NFκB inhibitor ammonium pyrrolidinedithiocar-
bamate (PDTC) (50 μM) (Sigma-Aldrich, Poole, UK).
Similarly, when studying the effects of integrin ανβ3 inhi-
bition, cells were cultured as above in the presence or
absence of an integrin ανβ3 neutralising antibody (10 μg/
ml) (Millipore, Co Durham, UK).
Determination of OPG concentration by ELISA
The concentration of OPG in the culture medium was
determined using an ELISA method. Briefly, 96 well plates
were coated with 2 μg/ml mouse monoclonal anti-human
OPG (R&D Systems, Abingdon, UK). An OPG standard
curve was created using recombinant human OPG (R&D
Systems) at concentrations ranging from 31.2 to 1000 pg/
ml. The secondary antibody, biotinylated anti-human
OPG (R&D Systems), was used at a concentration of 200
ng/ml. OPG protein levels were detected using streptavi-
din-horseradish peroxidase, followed by addition of sub-
strate solution (R & D Systems). After a 30 minute
incubation period, the reaction was stopped using 2 M
H2SO4 and the plate read at 450 nm on a Dynatech plate
reader using revelation software.
Real-time quantitative RT-PCR
RNA was extracted from cultured cells using TRI REA-
GENT™ (Sigma, Poole, UK) and reverse-transcribed using
Superscript II Reverse Transcriptase (Invitrogen, Paisley,
UK). Relative expression of OPG was compared to
GAPDH using probes and primers supplied in the
GAPDH and OPG TaqMan®  Gene Expression Assays
(Applied Biosystems, Warrington, UK). Real-time PCR
amplification of cDNA was performed using TaqMan®
Universal PCR mastermix (Applied Biosystems) on an
ABI7900 PCR system and results analysed using SDS 2.0
software (Applied Biosystems).
Statistical Analysis
Statistical analysis was performed using GraphPad
PRISM®  (version 5.0a). One-way analysis of variance
(ANOVA) and the Newman-Keuls test for post-hoc com-
parisons were used to test for significant differences
between groups.
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